The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044

British Journal of Pharmacology

Volumn 119, Issue 2, 1996, Pages 311-314

  Plumpton, Cristopher ^a   Ferro, Charles J ^b   Haynes, William G ^b   Webb, David J ^b   Davenport, Anthony P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Big endothelin; C terminal fragment; Endothelin; Human vasodilatation; Radioimmunoassay; Selective solid phase extraction

Indexed keywords

ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; RECEPTOR SUBTYPE; TAK 044;

ADULT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG BINDING; DRUG EFFECT; HEART INDEX; HEART LEFT VENTRICLE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE;

EID: 0029813755     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15987.x     Document Type: Article

References (24)

1. ARAI, H., HORI, S., ARAMORI, I., OHKUBO, H. & NAKANISHI, S. (1990). Cloning and expression of a cDNA encoding an endothelin receptor. Nature, 348, 730-732.
2. BATTISTINI, B., BOTTING, R. & WARNER, T.D. (1995). Endothelin: a knockout in London. Trends Pharmacol. Sci., 16, 217-222.
3. DAVENPORT, A.P. & MAGUIRE, J.J. (1994). Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans? Trends Pharmacol. Sci., 15, 9-11.
4. A sub-type. Br. J. Pharmacol., 114, 1110-1116.
5. DONCKIER, J., STOLERU, L., HAYASHIDA, W., VAN MECHELEN, H., SELVAIS, P., GALANTI, L., CLOZEL, J-P., KETELSLEGERS, J-M. & POULEUR, H. (1995). Role of endogenous endothelin-1 in experimental renal hypertension in dogs. Circulation, 92, 106-113.
6. FERRO, C.J. & WEBB, D.J. (1996). The clinical potential of endothelin receptor antagonists in cardiovascular medicine. Drugs, 51, 12-27.
7. GASIC, S., WAGNER, O.F., VIERHAPPER, H., NOWOTNY, P. & WALDÄUSL, W. (1992). Regional hemodynamic effects and clearance of endothelin-1 in humans: renal and peripheral tissues may contribute to the overall disposal of the peptide. J. Cardiovasc. Pharmacol., 19, 176-180.
8. HAYNES, W.G., FERRO, C.J., O'KANE, K.P.J., SOMMERVILLE, D., LOMAX, C.C. & WEBB, D.J. (1996). Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation, 93, 1860-1870.
9. HAYNES, W.G. & WEBB, D.J. (1994). Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet, 344, 852-854.
10. INOUE, A., YANAGISAWA, M., KIMURA, S., KASUYA, Y., MIYAUCHI, T., GOTO, K. & MASAKI, T. (1989). The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U.S.A., 86, 2863-2867.
11. B in human kidney. Kidney Int., 44, 36-42.
12. B. Biochem. Biophys. Res. Commun., 200, 1708-1712.
13. KIOWSKI, W., SÜTCH, G., HUNZIKER, P., MÜLLER, P., KIM, J., OECHSLIN, E., SCHMITT, R., JONES, R. & BERTEL, O. (1995). Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet, 346, 732-736.
14. LÖFFLER, B-M., BREU, V. & CLOZEL, M. (1993). Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma. FEBS Lett., 333, 108-110.
15. MCPHERSON, G. (1983). A practical computer-based approach to the analysis of radioligand binding experiments. Comput. Prog. Biomed., 17, 107-114.
16. A receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br. J. Pharmacol., 115, 191-197.
17. MUNSON, P.J. & RODBARD, D. (1980). LIGAND: A versatile computerized approach for the characterization of ligand binding systems. Analyt. Biochem., 107, 220-239.
18. PLUMPTON, C., ASHBY, M.J., KUC, R.E., O'REILLY, G. & DAVENPORT, A.P. (1996a). Expression of endothelin peptides and mRNA in the human heart. Clin. Sci., 90, 37-46.
19. PLUMPTON, C., FERRO, C.J., HAYNES, W.G., WEBB, D.J. & DAVENPORT, A.P. (1996b). The endothelin antagonist TAK-044 increases human plasma immunoreactive endothelin but not big endothelin or C-terminal fragment of big endothelin-1. Br. J. Pharmacol., 117, 32P.
20. PLUMPTON, C., HAYNES, W.G., WEBB, D.J. & DAVENPORT, A.P. (1995a). Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm. Br. J. Pharmacol., 116, 1821-1828.
21. PLUMPTON, C., HAYNES, W.G., WEBB, D.J. & DAVENPORT, A.P. (1995b). Measurement of C-terminal fragment of big endothelin-1: A novel method for assessing the generation of endothelin-1 in humans. J. Cardiovasc. Pharmacol., 26, s34-36.
22. SAKURAI, T., YANAGISAWA, M., TAKUWA, Y., MIYAZAKI, H., KIMURA, S., GOTO, K. & MASAKI, T. (1990). Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature, 348, 732-735.
23. TEERLINK, J.R., CARTEAUX, J-P., SPRECHER, U., LÖFFLER, B-M., CLOZEL, M & CLOZEL, J-P. (1995). Role of endogenous endothelin in normal hemodynamic status of anaesthetised dogs. Am. J. Physiol., 268 (Heart Circ. Physiol., 37), H432-H440.
24. WEITZBERG, E., AHLBORG, G. & LUNDBERG, J.M. (1991). Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues. Biochem. Biophys. Res. Commun., 180, 1298-1303.